Effect of BIA 2-093 on the Pharmacokinetics of a Combined Oral Contraceptive.

Inclusion Criteria: * Pre-menopausal female; * Able and willing to give written informed consent; * Aged 18 to 40 years, inclusive; * Not pregnant or breast-feeding; * Body mass index (BMI) between 19 and 30 kg/m2, inclusive; * Healthy as determined by medical history, physical examination, complete neurological examination, vital signs, and 12-lead ECG; * Clinical laboratory tests with clinically acceptable results at screening and admission to the first period; * Negative tests for HBsAg, anti-HCV Ab and HIV-1 and HIV-2 Ab at screening; * Negative test for drugs of abuse at screening; * Non-smoker or smokes less than 10 cigarettes or equivalent per day; * Agreed to either practice abstinence or use a double-barrier or intra-uterine device from screening until the follow-up visit; * Negative pregnancy test at screening and admission to the first period. Exclusion Criteria: * Had any contra-indication to the use of oral contraceptives; * Had experienced notable adverse events while on any oral contraceptive; * Had a history of alcoholism or drug abuse; * Had a relevant history or presence of respiratory, gastrointestinal, renal, hepatic,haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders; * Had acute gastrointestinal symptoms at the time of screening or admission to the first period; * Had a significant infection or inflammatory process at the time of screening or admission to the first period; * Had a relevant surgical history; * Had a relevant family history; * Had a history of relevant drug hypersensitivity (e.g., carbamazepine or oxcarbazepine); * Had used relevant prescription or over-the-counter medication within 2 weeks ofadmission to the first period; * Consumed more than 14 units of alcohol a week; * Had participated in any clinical trial within 3 months prior to screening; * Had previously received BIA 2-093; * Had donated or received any blood or blood products within 2 months prior to screening; * Was unlikely to co-operate with the requirements of the study.